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Poster Session II S391FMD in the palliative management of an unconscious patient
with Glucksberg Grade IV GVHD gut post HSCT. Use of
the device over the final 5 days of life was uneventful. Following
this experience we have gone on to use the FMD successfully in
3 further patients with severe acute GVHD gut post-HSCT. Ob-
served direct benefits for the patients include promotion of dig-
nity, facilitation of uninterrupted rest, absence of odour,
reduction of embarrassment and more comfortable access to vis-
itors. Clinical benefits included improved accuracy of fluid bal-
ance assessment, maintenance of skin integrity, absence of
healthcare associated infections & the ability to devote more
nursing time to the other needs of the patient. Our only negative
finding was that the FMD can leak, however this is minimal, and
can be reduced by regular flushing of the device. The device was
replaced every 28 days and was in use for up to 63 days, without
complications. We have found the FMD to promote the effective
& compassionate care of patients with severe GVHD gut.513
COLLABORATING WITH OUR COLLEAGUES TO ENHANCE CARE: A MUL-
TIDISCIPLINARY WORKFLOW FOR BUSULFAN PK SERUM LEVELS
Choo, K., Grant Navarro, P., Wallace, M.H. Memorial Sloan Kettering
Cancer Center, New York, NY
Significance and Background: Busulfan is administered as part of
a myeloblative conditioning regimen for allogeneic hematopoietic
stem cell transplant. Plasma pharmacokinetic analysis (PK) is used
to determine a patient’s Busulfan serum level. Maintaining therapeu-
tic levels of Busulfan decrease the risk of Busulfan related toxicity,
graft rejection and disease progression. In 2011 this NCI-designated
Comprehensive Cancer Center initiated processing of PK levels in-
stead of sending them to another facility almost 3000miles away.We
believe patient care is improved as the results are obtained the same
day instead of the next day providing the opportunity to adjust the
4th dose versus the 7th dose. This practice change required effective
collaboration between nursing, medicine, pharmacy and the clinical
laboratory.
Purpose:The purpose of in-house pharmacokinetic analysis (PK) is
to obtain results the same day and adjust the dose as necessary to
maintain a therapeutic serum level.
Interventions: Amultidisciplinary team developed a new RNwork-
flow for obtaining specifically timed specimens, an LIP order set, an
electronic notification when a Busulfan order is initiated, a workflow
for storing and transporting the specimens to the lab and a workflow
for the lab to verify receipt of specimens. A multidisciplinary educa-
tion plan was developed educating the medical, nursing, pharmacy
and clinical laboratory staff regarding the new in-house Busulfan
PK level process.
Evaluation: As a result of the new Busulfan PK level process,
levels are obtained with the first dose of Busulfan and results
are reported in the afternoon. On evening rounds, a determination
is made whether to adjust the 4th dose of Busulfan considering the
PK result.
Discussion:We believe that being able to adjust the dose of Bu-
sulfan earlier in the treatment process may help maintain a ther-
apeutic level enhancing the chance of a successful transplant
outcome.514
SAME QUALITY, FEWER RESOURCES: PREPARING PATIENTS FOR DIS-
CHARGE AFTER HEMATOPOIETIC STEM CELL TRANSPLANT
Blackburn, R.K., Doyle, K., Jewell, J. University of Texas MD Anderson
Cancer Center, Houston, TX
Background: Preparing for hospital discharge following hemato-
poietic stem cell transplantation (HSCT) involves extensive multi-
disciplinary teaching to patients and caregivers. Historically this
has been accomplished with printed materials, individualized teach-
ing, and formal group classes held weekly on the HSCT inpatientunit—a strategy that is labor and resource intensive, and inconve-
nient for out of town caregivers.
Purpose: The nursing leadership on a 64 bed HSCT unit at
a NCI-designated cancer center identified a need for patient/
caregiver educational methods that provided opportunities for pa-
tients to view repeatedly, and for their caregivers to view from
home.
Intervention: A multidisciplinary health care team from the
HSCT unit developed scripts for 16 minute discharge films aimed
at either allogeneic or autologous patients that could be viewed on
television through the patient education system in patient rooms,
or could be accessed as 2 minute segments in links through the in-
stitutional intranet. Caregivers receive access from HSCT patients
to view the web based chapters that cover all aspects of care after
discharge.
Evaluation: For one month HSCT inpatients viewed both the
video, and attended the existing 1 hour discharge class, and then
completed an evaluation of which form of education they preferred.
Of the 38 evaluations returned, patients overwhelming reported
that the content covered in the video prepared them for discharge,
and appreciated the ability to view it repeatedly in the comfort of
their room. Patients did, however, request an opportunity to ask
questions in a live format. Based on these results, 30 min weekly
question and answer sessions were scheduled that patients/families
may attend after viewing the video. Attendance at these sessions has
been low, as many patients feel the videos adequately addressed
their concerns.
Discussion:One of the biggest challenges facing healthcare organi-
zations in today’s economic climate is maintaining high quality pa-
tient care programs with fewer financial resources. Preparing
HSCTpatients for discharge from the hospital involves extensive ed-
ucation of complex post transplant guidelines. Moving from labor
and resource intensive individual classes to film and web based appli-
cations are useful ways to assure patient education content is thor-
oughly covered. Providing 30-minute weekly scheduled question
and answer sessions allows patients an opportunity to have concerns
addressed.515
NON-PHARMACOLOGICAL STRATEGIES TO PREVENT NEUTROPENIC FE-
VER IN HEMATOLOGIC MALIGNANCY
Weiner, H., Lunsford, V., Potter, P. Barnes Jewish Hospital, St. Louis,
MO
Neutropenia is often an inevitable part of treating hematologic
malignancies. It is the most common cause of limiting the dose of
chemotherapy and if neutropenia occurs, it puts a patient at
a much higher risk of developing an infection that can quickly be-
come life threatening. As such, it is a goal for nurses to prevent
neutropenic infections as much as possible. Because the first
sign, and often only sign, of a neutropenic infection is fever, on-
cology staff use a fever as an objective measure to gauge the health
status of the patient. In the past, common nursing interventions
used to prevent neutropenic fever have included protective isola-
tion and neutropenic diet. However, there is little data to support
the use of either. In addition, these measures are difficult to ad-
here to and create a feeling of isolation in the patient. The pur-
pose of this review of literature is to critically analyze current
literature to determine if there are data that indicate that neutro-
penic diet and protective isolation are effective forms of prevent-
ing neutropenic fever. CINAHL, MEDLINE and the Cochrane
database were searched for key words ‘‘neutropenia’’, ‘‘fever’’, ‘‘in-
fection’’, ‘‘prevention’’, ‘‘isolation’’, and ‘‘diet’’, with a time limita-
tion from 2001 until present. Additional articles were identified
from the reference lists of these articles. Twelve articles were
identified as being pertinent to the subject matter. Both qualitative
and quantitative studies were included in the review. The data
found in the literature review does not support the use of neutro-
penic diet or reverse isolation for the prevention of neutropenic
fever. Instead of using resources and time on these interventions,
nurses should emphasize that patients employ proper hand hy-
giene and that fruits and vegetables are thoroughly washed before
eating them.
